• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Benzinga's Top Ratings Upgrades, Downgrades For July 7, 2022

    7/7/22 10:04:41 AM ET
    $ABTX
    $ADVM
    $ALEC
    $AMTI
    Major Banks
    Finance
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ABTX alert in real time by email

    Upgrades

    For Pacific Premier Bancorp Inc (NASDAQ:PPBI), Raymond James upgraded the previous rating of Outperform to Strong Buy. In the first quarter, Pacific Premier Bancorp showed an EPS of $0.70, compared to $0.72 from the year-ago quarter. At the moment, the stock has a 52-week-high of $45.24 and a 52-week-low of $27.92. Pacific Premier Bancorp closed at $30.08 at the end of the last trading period.

    For Heritage Commerce Corp (NASDAQ:HTBK), Raymond James upgraded the previous rating of Outperform to Strong Buy. For the first quarter, Heritage Commerce had an EPS of $0.21, compared to year-ago quarter EPS of $0.19. The current stock performance of Heritage Commerce shows a 52-week-high of $12.94 and a 52-week-low of $10.43. Moreover, at the end of the last trading period, the closing price was at $10.82.

    Citigroup upgraded the previous rating for Lamar Advertising Co (NASDAQ:LAMR) from Neutral to Buy. In the first quarter, Lamar Advertising showed an EPS of $0.91, compared to $0.38 from the year-ago quarter. The current stock performance of Lamar Advertising shows a 52-week-high of $124.32 and a 52-week-low of $83.96. Moreover, at the end of the last trading period, the closing price was at $88.41.

    According to Raymond James, the prior rating for Allegiance Bancshares Inc (NASDAQ:ABTX) was changed from Market Perform to Outperform. For the first quarter, Allegiance Bancshares had an EPS of $0.91, compared to year-ago quarter EPS of $0.89. At the moment, the stock has a 52-week-high of $46.00 and a 52-week-low of $34.30. Allegiance Bancshares closed at $39.02 at the end of the last trading period.

    Raymond James upgraded the previous rating for Texas Capital Bancshares Inc (NASDAQ:TCBI) from Outperform to Strong Buy. Texas Capital Bancshares earned $0.69 in the first quarter, compared to $1.33 in the year-ago quarter. The stock has a 52-week-high of $71.60 and a 52-week-low of $48.79. At the end of the last trading period, Texas Capital Bancshares closed at $53.09.

    For Regions Financial Corp (NYSE:RF), Raymond James upgraded the previous rating of Market Perform to Outperform. Regions Financial earned $0.55 in the first quarter, compared to $0.63 in the year-ago quarter. At the moment, the stock has a 52-week-high of $25.57 and a 52-week-low of $18.02. Regions Financial closed at $18.56 at the end of the last trading period.

    According to Raymond James, the prior rating for First Mid Bancshares Inc (NASDAQ:FMBH) was changed from Market Perform to Outperform. For the first quarter, First Mid Bancshares had an EPS of $0.96, compared to year-ago quarter EPS of $0.88. The stock has a 52-week-high of $45.84 and a 52-week-low of $35.05. At the end of the last trading period, First Mid Bancshares closed at $36.22.

    According to Raymond James, the prior rating for First Merchants Corp (NASDAQ:FRME) was changed from Outperform to Strong Buy. For the first quarter, First Merchants had an EPS of $0.88, compared to year-ago quarter EPS of $0.91. At the moment, the stock has a 52-week-high of $46.12 and a 52-week-low of $35.07. First Merchants closed at $35.87 at the end of the last trading period.

    Raymond James upgraded the previous rating for Carter Bankshares Inc (NASDAQ:CARE) from Market Perform to Outperform. Carter Bankshares earned $0.36 in the first quarter, compared to $0.36 in the year-ago quarter. At the moment, the stock has a 52-week-high of $17.99 and a 52-week-low of $10.02. Carter Bankshares closed at $13.15 at the end of the last trading period.

    For Pinnacle Financial Partners Inc (NASDAQ:PNFP), Raymond James upgraded the previous rating of Market Perform to Outperform. In the first quarter, Pinnacle Finl Partners showed an EPS of $1.65, compared to $1.61 from the year-ago quarter. At the moment, the stock has a 52-week-high of $111.31 and a 52-week-low of $67.90. Pinnacle Finl Partners closed at $72.46 at the end of the last trading period.

    For PPL Corp (NYSE:PPL), Evercore ISI Group upgraded the previous rating of In-Line to Outperform. For the first quarter, PPL had an EPS of $0.41, compared to year-ago quarter EPS of $0.28. The current stock performance of PPL shows a 52-week-high of $30.71 and a 52-week-low of $24.98. Moreover, at the end of the last trading period, the closing price was at $27.05.

    According to Truist Securities, the prior rating for Adverum Biotechnologies Inc (NASDAQ:ADVM) was changed from Hold to Buy. For the first quarter, Adverum Biotechnologies had an EPS of $0.38, compared to year-ago quarter EPS of $0.29. At the moment, the stock has a 52-week-high of $3.66 and a 52-week-low of $0.80. Adverum Biotechnologies closed at $1.23 at the end of the last trading period.

    For EPR Properties (NYSE:EPR), Janney Montgomery Scott upgraded the previous rating of Neutral to Buy. EPR Props earned $1.10 in the first quarter, compared to $0.48 in the year-ago quarter. The stock has a 52-week-high of $56.38 and a 52-week-low of $41.14. At the end of the last trading period, EPR Props closed at $47.14.

    According to BTIG, the prior rating for 1Life Healthcare Inc (NASDAQ:ONEM) was changed from Neutral to Buy. For the first quarter, 1Life Healthcare had an EPS of $0.47, compared to year-ago quarter EPS of $0.29. The current stock performance of 1Life Healthcare shows a 52-week-high of $33.72 and a 52-week-low of $5.94. Moreover, at the end of the last trading period, the closing price was at $10.28.

    According to Wells Fargo, the prior rating for Bank of N.T Butterfield & Son Ltd (NYSE:NTB) was changed from Equal-Weight to Overweight. For the first quarter, Bank of N.T Butterfield had an EPS of $0.90, compared to year-ago quarter EPS of $0.83. The stock has a 52-week-high of $41.69 and a 52-week-low of $28.67. At the end of the last trading period, Bank of N.T Butterfield closed at $30.94.

    Daiwa Capital upgraded the previous rating for Merck & Co Inc (NYSE:MRK) from Hold to Outperform. For the first quarter, Merck & Co had an EPS of $2.14, compared to year-ago quarter EPS of $1.40. At the moment, the stock has a 52-week-high of $95.72 and a 52-week-low of $70.89. Merck & Co closed at $93.13 at the end of the last trading period.

    According to RBC Capital, the prior rating for Cerence Inc (NASDAQ:CRNC) was changed from Underperform to Sector Perform. For the second quarter, Cerence had an EPS of $0.33, compared to year-ago quarter EPS of $0.69. The current stock performance of Cerence shows a 52-week-high of $126.40 and a 52-week-low of $24.35. Moreover, at the end of the last trading period, the closing price was at $25.74.

    Jefferies upgraded the previous rating for Tenaris SA (NYSE:TS) from Hold to Buy. Tenaris earned $0.85 in the first quarter, compared to $0.18 in the year-ago quarter. At the moment, the stock has a 52-week-high of $34.76 and a 52-week-low of $18.80. Tenaris closed at $22.89 at the end of the last trading period.

    See all analyst ratings upgrades.

    Downgrades

    According to Raymond James, the prior rating for Preferred Bank (NASDAQ:PFBC) was changed from Outperform to Market Perform. In the first quarter, Preferred Bank showed an EPS of $1.74, compared to $1.42 from the year-ago quarter. At the moment, the stock has a 52-week-high of $81.97 and a 52-week-low of $57.27. Preferred Bank closed at $69.27 at the end of the last trading period.

    According to Scotiabank, the prior rating for Cornerstone Building Brands Inc (NYSE:CNR) was changed from Sector Outperform to Sector Perform. Cornerstone Building earned $0.66 in the first quarter, compared to $0.03 in the year-ago quarter. At the moment, the stock has a 52-week-high of $24.61 and a 52-week-low of $13.51. Cornerstone Building closed at $24.54 at the end of the last trading period.

    Raymond James downgraded the previous rating for FS Bancorp Inc (NASDAQ:FSBW) from Outperform to Market Perform. FS Bancorp earned $0.81 in the first quarter, compared to $1.35 in the year-ago quarter. The stock has a 52-week-high of $71.68 and a 52-week-low of $28.09. At the end of the last trading period, FS Bancorp closed at $28.76.

    For Canadian Pacific Railway Ltd (NYSE:CP), Scotiabank downgraded the previous rating of Sector Outperform to Sector Perform. In the first quarter, Canadian Pacific Railway showed an EPS of $0.53, compared to $0.71 from the year-ago quarter. The current stock performance of Canadian Pacific Railway shows a 52-week-high of $84.22 and a 52-week-low of $64.37. Moreover, at the end of the last trading period, the closing price was at $71.65.

    According to Raymond James, the prior rating for Sierra Bancorp (NASDAQ:BSRR) was changed from Outperform to Market Perform. For the first quarter, Sierra Bancorp had an EPS of $0.49, compared to year-ago quarter EPS of $0.72. At the moment, the stock has a 52-week-high of $28.92 and a 52-week-low of $20.77. Sierra Bancorp closed at $21.42 at the end of the last trading period.

    Oppenheimer downgraded the previous rating for DiaMedica Therapeutics Inc (NASDAQ:DMAC) from Outperform to Perform. For the first quarter, DiaMedica Therapeutics had an EPS of $0.13, compared to year-ago quarter EPS of $0.19. The current stock performance of DiaMedica Therapeutics shows a 52-week-high of $4.82 and a 52-week-low of $1.62. Moreover, at the end of the last trading period, the closing price was at $2.02.

    Jefferies downgraded the previous rating for CytomX Therapeutics Inc (NASDAQ:CTMX) from Buy to Hold. CytomX Therapeutics earned $0.37 in the first quarter, compared to $0.26 in the year-ago quarter. The current stock performance of CytomX Therapeutics shows a 52-week-high of $7.53 and a 52-week-low of $1.50. Moreover, at the end of the last trading period, the closing price was at $1.97.

    For Kohl's Corp (NYSE:KSS), Gordon Haskett downgraded the previous rating of Accumulate to Hold. For the first quarter, Kohl's had an EPS of $0.11, compared to year-ago quarter EPS of $1.05. The current stock performance of Kohl's shows a 52-week-high of $64.38 and a 52-week-low of $27.31. Moreover, at the end of the last trading period, the closing price was at $27.37.

    According to Argus Research, the prior rating for United Airlines Holdings Inc (NASDAQ:UAL) was changed from Buy to Hold. In the first quarter, United Airlines Holdings showed an EPS of $4.24, compared to $4.29 from the year-ago quarter. At the moment, the stock has a 52-week-high of $54.52 and a 52-week-low of $30.54. United Airlines Holdings closed at $36.66 at the end of the last trading period.

    According to Raymond James, the prior rating for Bank OZK (NASDAQ:OZK) was changed from Outperform to Market Perform. In the first quarter, Bank OZK showed an EPS of $1.02, compared to $1.11 from the year-ago quarter. The stock has a 52-week-high of $51.39 and a 52-week-low of $34.79. At the end of the last trading period, Bank OZK closed at $37.82.

    For PacWest Bancorp (NASDAQ:PACW), Raymond James downgraded the previous rating of Strong Buy to Market Perform. PacWest Banc earned $1.01 in the first quarter, compared to $1.27 in the year-ago quarter. At the moment, the stock has a 52-week-high of $51.81 and a 52-week-low of $25.60. PacWest Banc closed at $26.96 at the end of the last trading period.

    For Horizon Bancorp (IN) (NASDAQ:HBNC), Raymond James downgraded the previous rating of Strong Buy to Outperform. For the first quarter, Horizon Bancorp had an EPS of $0.54, compared to year-ago quarter EPS of $0.44. At the moment, the stock has a 52-week-high of $23.80 and a 52-week-low of $15.66. Horizon Bancorp closed at $17.82 at the end of the last trading period.

    Raymond James downgraded the previous rating for Dime Community Bancshares Inc (NASDAQ:DCOM) from Strong Buy to Outperform. Dime Community Bancshares earned $0.82 in the first quarter, compared to $0.94 in the year-ago quarter. The stock has a 52-week-high of $38.35 and a 52-week-low of $28.36. At the end of the last trading period, Dime Community Bancshares closed at $30.30.

    Raymond James downgraded the previous rating for First Financial Corp (NASDAQ:THFF) from Outperform to Market Perform. First Financial earned $1.67 in the first quarter, compared to $0.95 in the year-ago quarter. The stock has a 52-week-high of $47.10 and a 52-week-low of $37.70. At the end of the last trading period, First Financial closed at $45.00.

    For FVCBankcorp Inc (NASDAQ:FVCB), Raymond James downgraded the previous rating of Strong Buy to Outperform. FVCBankcorp earned $0.46 in the first quarter, compared to $0.38 in the year-ago quarter. The stock has a 52-week-high of $21.90 and a 52-week-low of $16.43. At the end of the last trading period, FVCBankcorp closed at $18.97.

    For Lakeland Bancorp Inc (NASDAQ:LBAI), Raymond James downgraded the previous rating of Strong Buy to Outperform. For the first quarter, Lakeland Bancorp had an EPS of $0.25, compared to year-ago quarter EPS of $0.45. The stock has a 52-week-high of $20.69 and a 52-week-low of $14.40. At the end of the last trading period, Lakeland Bancorp closed at $14.82.

    For Southern Copper Corp (NYSE:SCCO), Wolfe Research downgraded the previous rating of Peer Perform to Underperform. For the first quarter, Southern Copper had an EPS of $1.02, compared to year-ago quarter EPS of $0.99. At the moment, the stock has a 52-week-high of $79.31 and a 52-week-low of $46.50. Southern Copper closed at $48.76 at the end of the last trading period.

    According to Raymond James, the prior rating for Meta Financial Group Inc (NASDAQ:CASH) was changed from Strong Buy to Outperform. Meta Financial Group earned $1.73 in the second quarter, compared to $1.84 in the year-ago quarter. The current stock performance of Meta Financial Group shows a 52-week-high of $65.95 and a 52-week-low of $36.02. Moreover, at the end of the last trading period, the closing price was at $40.75.

    For CytomX Therapeutics Inc (NASDAQ:CTMX), Wedbush downgraded the previous rating of Outperform to Neutral. In the first quarter, CytomX Therapeutics showed an EPS of $0.37, compared to $0.26 from the year-ago quarter. The current stock performance of CytomX Therapeutics shows a 52-week-high of $7.53 and a 52-week-low of $1.50. Moreover, at the end of the last trading period, the closing price was at $1.97.

    Raymond James downgraded the previous rating for SmartFinancial Inc (NASDAQ:SMBK) from Strong Buy to Outperform. For the first quarter, SmartFinancial had an EPS of $0.51, compared to year-ago quarter EPS of $0.65. At the moment, the stock has a 52-week-high of $28.63 and a 52-week-low of $22.63. SmartFinancial closed at $23.80 at the end of the last trading period.

    According to TD Securities, the prior rating for Resolute Forest Products Inc (NYSE:RFP) was changed from Buy to Hold. Resolute Forest Prods earned $2.26 in the first quarter, compared to $1.45 in the year-ago quarter. The current stock performance of Resolute Forest Prods shows a 52-week-high of $20.71 and a 52-week-low of $9.84. Moreover, at the end of the last trading period, the closing price was at $20.36.

    Raymond James downgraded the previous rating for First Commonwealth Financial Corp (NYSE:FCF) from Outperform to Market Perform. For the first quarter, First Commonwealth had an EPS of $0.29, compared to year-ago quarter EPS of $0.41. The stock has a 52-week-high of $17.63 and a 52-week-low of $12.36. At the end of the last trading period, First Commonwealth closed at $13.58.

    According to Raymond James, the prior rating for CapStar Financial Holdings Inc (NASDAQ:CSTR) was changed from Outperform to Market Perform. In the first quarter, CapStar Finl Hldgs showed an EPS of $0.48, compared to $0.50 from the year-ago quarter. The current stock performance of CapStar Finl Hldgs shows a 52-week-high of $22.74 and a 52-week-low of $18.92. Moreover, at the end of the last trading period, the closing price was at $19.57.

    For Cambridge Bancorp (NASDAQ:CATC), Raymond James downgraded the previous rating of Outperform to Market Perform. Cambridge earned $1.89 in the first quarter, compared to $1.92 in the year-ago quarter. At the moment, the stock has a 52-week-high of $97.57 and a 52-week-low of $77.62. Cambridge closed at $82.45 at the end of the last trading period.

    Raymond James downgraded the previous rating for Live Oak Bancshares Inc (NASDAQ:LOB) from Outperform to Market Perform. For the first quarter, Live Oak Bancshares had an EPS of $0.76, compared to year-ago quarter EPS of $0.88. At the moment, the stock has a 52-week-high of $99.89 and a 52-week-low of $32.05. Live Oak Bancshares closed at $33.40 at the end of the last trading period.

    According to Raymond James, the prior rating for Veritex Holdings Inc (NASDAQ:VBTX) was changed from Strong Buy to Outperform. In the first quarter, Veritex Holdings showed an EPS of $0.66, compared to $0.64 from the year-ago quarter. The current stock performance of Veritex Holdings shows a 52-week-high of $45.36 and a 52-week-low of $27.28. Moreover, at the end of the last trading period, the closing price was at $29.82.

    Raymond James downgraded the previous rating for PNC Financial Services Group Inc (NYSE:PNC) from Outperform to Market Perform. PNC Financial Services Gr earned $3.29 in the first quarter, compared to $4.10 in the year-ago quarter. The stock has a 52-week-high of $228.14 and a 52-week-low of $149.51. At the end of the last trading period, PNC Financial Services Gr closed at $160.03.

    According to Raymond James, the prior rating for Hilltop Holdings Inc (NYSE:HTH) was changed from Market Perform to Underperform. In the first quarter, Hilltop Holdings showed an EPS of $0.28, compared to $1.46 from the year-ago quarter. At the moment, the stock has a 52-week-high of $38.47 and a 52-week-low of $25.07. Hilltop Holdings closed at $27.42 at the end of the last trading period.

    For Guaranty Bancshares Inc (NASDAQ:GNTY), Raymond James downgraded the previous rating of Outperform to Market Perform. For the first quarter, Guaranty Bancshares had an EPS of $0.88, compared to year-ago quarter EPS of $0.94. The current stock performance of Guaranty Bancshares shows a 52-week-high of $44.60 and a 52-week-low of $31.65. Moreover, at the end of the last trading period, the closing price was at $36.35.

    According to JP Morgan, the prior rating for Otis Worldwide Corp (NYSE:OTIS) was changed from Overweight to Neutral. Otis Worldwide earned $0.77 in the first quarter, compared to $0.72 in the year-ago quarter. The current stock performance of Otis Worldwide shows a 52-week-high of $92.84 and a 52-week-low of $66.97. Moreover, at the end of the last trading period, the closing price was at $71.26.

    BTIG downgraded the previous rating for T2 Biosystems Inc (NASDAQ:TTOO) from Buy to Neutral. T2 Biosystems earned $0.10 in the first quarter, compared to $0.07 in the year-ago quarter. The current stock performance of T2 Biosystems shows a 52-week-high of $1.23 and a 52-week-low of $0.15. Moreover, at the end of the last trading period, the closing price was at $0.16.

    Berenberg downgraded the previous rating for Rio Tinto PLC (NYSE:RIO) from Hold to Sell. The stock has a 52-week-high of $89.51 and a 52-week-low of $56.02. At the end of the last trading period, Rio Tinto closed at $57.26.

    B of A Securities downgraded the previous rating for Kohl's Corp (NYSE:KSS) from Neutral to Underperform. In the first quarter, Kohl's showed an EPS of $0.11, compared to $1.05 from the year-ago quarter. The stock has a 52-week-high of $64.38 and a 52-week-low of $27.31. At the end of the last trading period, Kohl's closed at $27.37.

    According to B of A Securities, the prior rating for Sealed Air Corp (NYSE:SEE) was changed from Buy to Neutral. Sealed Air earned $1.12 in the first quarter, compared to $0.78 in the year-ago quarter. The stock has a 52-week-high of $70.72 and a 52-week-low of $53.87. At the end of the last trading period, Sealed Air closed at $58.43.

    Baird downgraded the previous rating for Aspen Technology Inc (NASDAQ:AZPN) from Outperform to Neutral. Aspen Technology earned $1.38 in the third quarter, compared to $1.05 in the year-ago quarter. The stock has a 52-week-high of $210.59 and a 52-week-low of $122.29. At the end of the last trading period, Aspen Technology closed at $191.34.

    Keybanc downgraded the previous rating for Vtex (NYSE:VTEX) from Overweight to Sector Weight. For the first quarter, Vtex had an EPS of $0.10, compared to year-ago quarter EPS of $0.07. At the moment, the stock has a 52-week-high of $33.36 and a 52-week-low of $2.74. Vtex closed at $3.09 at the end of the last trading period.

    Keybanc downgraded the previous rating for Blend Labs Inc (NYSE:BLND) from Overweight to Sector Weight. The current stock performance of Blend Labs shows a 52-week-high of $21.04 and a 52-week-low of $2.17. Moreover, at the end of the last trading period, the closing price was at $2.70.

    UBS downgraded the previous rating for Kellogg Co (NYSE:K) from Buy to Neutral. Kellogg earned $1.10 in the first quarter, compared to $1.11 in the year-ago quarter. The stock has a 52-week-high of $75.56 and a 52-week-low of $59.54. At the end of the last trading period, Kellogg closed at $72.75.

    According to Citigroup, the prior rating for Consolidated Communications Holdings Inc (NASDAQ:CNSL) was changed from Neutral to Sell. For the first quarter, Consolidated Comms Hldgs had an EPS of $0.02, compared to year-ago quarter EPS of $0.21. The stock has a 52-week-high of $9.70 and a 52-week-low of $4.51. At the end of the last trading period, Consolidated Comms Hldgs closed at $6.98.

    For Bank OZK (NASDAQ:OZK), Wells Fargo downgraded the previous rating of Overweight to Equal-Weight. Bank OZK earned $1.02 in the first quarter, compared to $1.11 in the year-ago quarter. The stock has a 52-week-high of $51.39 and a 52-week-low of $34.79. At the end of the last trading period, Bank OZK closed at $37.82.

    For Applied Molecular Transport Inc (NASDAQ:AMTI), Jefferies downgraded the previous rating of Buy to Hold. In the first quarter, Applied Molecular showed an EPS of $1.10, compared to $0.58 from the year-ago quarter. The stock has a 52-week-high of $46.48 and a 52-week-low of $1.97. At the end of the last trading period, Applied Molecular closed at $2.32.

    According to RBC Capital, the prior rating for Boston Beer Co Inc (NYSE:SAM) was changed from Outperform to Sector Perform. Boston Beer Co earned $0.16 in the first quarter, compared to $5.26 in the year-ago quarter. The current stock performance of Boston Beer Co shows a 52-week-high of $990.40 and a 52-week-low of $287.00. Moreover, at the end of the last trading period, the closing price was at $306.23.

    Mizuho downgraded the previous rating for CytomX Therapeutics Inc (NASDAQ:CTMX) from Buy to Neutral. For the first quarter, CytomX Therapeutics had an EPS of $0.37, compared to year-ago quarter EPS of $0.26. The current stock performance of CytomX Therapeutics shows a 52-week-high of $7.53 and a 52-week-low of $1.50. Moreover, at the end of the last trading period, the closing price was at $1.97.

    Piper Sandler downgraded the previous rating for CytomX Therapeutics Inc (NASDAQ:CTMX) from Overweight to Neutral. For the first quarter, CytomX Therapeutics had an EPS of $0.37, compared to year-ago quarter EPS of $0.26. At the moment, the stock has a 52-week-high of $7.53 and a 52-week-low of $1.50. CytomX Therapeutics closed at $1.97 at the end of the last trading period.

    See all analyst ratings downgrades.

    Initiations

    With a Neutral rating, JP Morgan initiated coverage on Rover Group Inc (NASDAQ:ROVR). The price target seems to have been set at $5.00 for Rover Group. For the first quarter, Rover Group had an EPS of $0.08, compared to year-ago quarter EPS of $0.35. The stock has a 52-week-high of $15.59 and a 52-week-low of $3.61. At the end of the last trading period, Rover Group closed at $4.05.

    With an Outperform rating, Cowen & Co. initiated coverage on CTI BioPharma Corp (NASDAQ:CTIC). The price target seems to have been set at $10.00 for CTI BioPharma. CTI BioPharma earned $0.37 in the first quarter, compared to $0.23 in the year-ago quarter. The stock has a 52-week-high of $6.52 and a 52-week-low of $1.43. At the end of the last trading period, CTI BioPharma closed at $6.00.

    With a Buy rating, Roth Capital initiated coverage on Kalera PLC (NASDAQ:KAL). The price target seems to have been set at $6.00 for Kalera. The stock has a 52-week-high of $13.30 and a 52-week-low of $2.53. At the end of the last trading period, Kalera closed at $4.41.

    With a Buy rating, Canaccord Genuity initiated coverage on New Relic Inc (NYSE:NEWR). The price target seems to have been set at $81.00 for New Relic. In the fourth quarter, New Relic showed an EPS of $0.24, compared to $0.27 from the year-ago quarter. The stock has a 52-week-high of $129.70 and a 52-week-low of $41.66. At the end of the last trading period, New Relic closed at $52.24.

    With a Buy rating, EF Hutton initiated coverage on Superior Group Of Companies Inc (NASDAQ:SGC). The price target seems to have been set at $29.00 for Superior Gr of Cos. In the first quarter, Superior Gr of Cos showed an EPS of $0.32, compared to $0.66 from the year-ago quarter. The current stock performance of Superior Gr of Cos shows a 52-week-high of $27.25 and a 52-week-low of $14.57. Moreover, at the end of the last trading period, the closing price was at $17.82.

    With a Hold rating, Jefferies initiated coverage on EVgo Inc (NASDAQ:EVGO). The price target seems to have been set at $5.50 for EVgo. The current stock performance of EVgo shows a 52-week-high of $19.59 and a 52-week-low of $5.28. Moreover, at the end of the last trading period, the closing price was at $5.60.

    Needham initiated coverage on Duolingo Inc (NASDAQ:DUOL) with a Buy rating. The price target for Duolingo is set to $115.00. In the first quarter, Duolingo showed an EPS of $0.31, compared to $1.04 from the year-ago quarter. The current stock performance of Duolingo shows a 52-week-high of $205.00 and a 52-week-low of $60.50. Moreover, at the end of the last trading period, the closing price was at $96.95.

    With a Buy rating, Needham initiated coverage on GitLab Inc (NASDAQ:GTLB). The price target seems to have been set at $70.00 for GitLab. In the first quarter, GitLab showed an EPS of $0.18, compared to $0.53 from the year-ago quarter. At the moment, the stock has a 52-week-high of $137.00 and a 52-week-low of $30.74. GitLab closed at $56.01 at the end of the last trading period.

    Chardan Capital initiated coverage on EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) with a Buy rating. The price target for EyePoint Pharmaceuticals is set to $21.00. For the first quarter, EyePoint Pharmaceuticals had an EPS of $0.56, compared to year-ago quarter EPS of $0.50. The current stock performance of EyePoint Pharmaceuticals shows a 52-week-high of $21.50 and a 52-week-low of $7.00. Moreover, at the end of the last trading period, the closing price was at $7.79.

    Mizuho initiated coverage on BioXcel Therapeutics Inc (NASDAQ:BTAI) with a Buy rating. The price target for BioXcel Therapeutics is set to $19.00. In the first quarter, BioXcel Therapeutics showed an EPS of $1.12, compared to $1.08 from the year-ago quarter. The stock has a 52-week-high of $36.49 and a 52-week-low of $8.79. At the end of the last trading period, BioXcel Therapeutics closed at $15.85.

    Mizuho initiated coverage on Intra-Cellular Therapies Inc (NASDAQ:ITCI) with a Buy rating. The price target for Intra-Cellular Therapies is set to $74.00. In the first quarter, Intra-Cellular Therapies showed an EPS of $0.78, compared to $0.65 from the year-ago quarter. The stock has a 52-week-high of $66.00 and a 52-week-low of $28.40. At the end of the last trading period, Intra-Cellular Therapies closed at $56.17.

    With a Buy rating, Mizuho initiated coverage on Athira Pharma Inc (NASDAQ:ATHA). The price target seems to have been set at $6.00 for Athira Pharma. Athira Pharma earned $0.56 in the first quarter, compared to $0.25 in the year-ago quarter. The stock has a 52-week-high of $16.65 and a 52-week-low of $2.53. At the end of the last trading period, Athira Pharma closed at $3.39.

    Mizuho initiated coverage on Alector Inc (NASDAQ:ALEC) with a Buy rating. The price target for Alector is set to $15.00. In the first quarter, Alector showed an EPS of $0.54, compared to $0.66 from the year-ago quarter. At the moment, the stock has a 52-week-high of $40.39 and a 52-week-low of $7.50. Alector closed at $11.56 at the end of the last trading period.

    With a Neutral rating, Mizuho initiated coverage on Cerevel Therapeutics Holdings Inc (NASDAQ:CERE). The price target seems to have been set at $30.00 for Cerevel Therapeutics Hldg. Cerevel Therapeutics Hldg earned $0.46 in the first quarter, compared to $0.40 in the year-ago quarter. At the moment, the stock has a 52-week-high of $46.16 and a 52-week-low of $19.59. Cerevel Therapeutics Hldg closed at $30.00 at the end of the last trading period.

    Mizuho initiated coverage on Harmony Biosciences Holdings Inc (NASDAQ:HRMY) with a Buy rating. The price target for Harmony Biosciences is set to $64.00. In the first quarter, Harmony Biosciences showed an EPS of $0.51, compared to $0.38 from the year-ago quarter. At the moment, the stock has a 52-week-high of $55.60 and a 52-week-low of $25.09. Harmony Biosciences closed at $54.92 at the end of the last trading period.

    See all analyst ratings initiations.

    Get the next $ABTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABTX
    $ADVM
    $ALEC
    $AMTI

    CompanyDatePrice TargetRatingAnalyst
    Duolingo Inc.
    $DUOL
    2/27/2026$100.00Buy → Hold
    Truist
    Duolingo Inc.
    $DUOL
    2/27/2026$100.00Buy → Neutral
    BofA Securities
    Duolingo Inc.
    $DUOL
    2/27/2026$100.00Sector Outperform → Sector Perform
    Scotiabank
    Duolingo Inc.
    $DUOL
    2/27/2026$95.00Overweight → Neutral
    Analyst
    Duolingo Inc.
    $DUOL
    2/27/2026$114.00Outperform → In-line
    Evercore ISI
    Duolingo Inc.
    $DUOL
    2/27/2026$100.00Overweight → Equal-Weight
    Morgan Stanley
    Duolingo Inc.
    $DUOL
    2/27/2026$101.00Buy → Neutral
    Citigroup
    Southern Copper Corporation
    $SCCO
    2/26/2026$175.00Neutral → Underperform
    BofA Securities
    More analyst ratings

    $ABTX
    $ADVM
    $ALEC
    $AMTI
    SEC Filings

    View All

    SEC Form PRE 14A filed by Texas Capital Bancshares Inc.

    PRE 14A - TEXAS CAPITAL BANCSHARES INC/TX (0001077428) (Filer)

    2/27/26 4:08:06 PM ET
    $TCBI
    Major Banks
    Finance

    Texas Capital Bancshares Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits, Entry into a Material Definitive Agreement

    8-K - TEXAS CAPITAL BANCSHARES INC/TX (0001077428) (Filer)

    2/27/26 4:05:41 PM ET
    $TCBI
    Major Banks
    Finance

    SEC Form 10-K filed by Southern Copper Corporation

    10-K - SOUTHERN COPPER CORP/ (0001001838) (Filer)

    2/27/26 3:29:39 PM ET
    $SCCO
    Metal Mining
    Basic Materials

    $ABTX
    $ADVM
    $ALEC
    $AMTI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for IGALMI issued to BIOXCEL THERAPEUTICS, INC.

    Submission status for BIOXCEL THERAPEUTICS, INC.'s drug IGALMI (ORIG-1) with active ingredient DEXMEDETOMIDINE has changed to 'Approval' on 04/05/2022. Application Category: NDA, Application Number: 215390, Application Classification: Type 3 - New Dosage Form

    4/6/22 2:18:32 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABTX
    $ADVM
    $ALEC
    $AMTI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEVP, CHIEF CREDIT OFFICER Kallsen Tony E covered exercise/tax liability with 351 shares and was granted 4,358 shares, increasing direct ownership by 24% to 20,619 units (SEC Form 4)

    4 - Carter Bankshares, Inc. (0001829576) (Issuer)

    2/27/26 11:57:34 AM ET
    $CARE
    Major Banks
    Finance

    SENIOR EXECUTIVE VP, CFO Bell Wendy S. covered exercise/tax liability with 554 shares and was granted 5,805 shares, increasing direct ownership by 15% to 40,658 units (SEC Form 4)

    4 - Carter Bankshares, Inc. (0001829576) (Issuer)

    2/27/26 11:56:37 AM ET
    $CARE
    Major Banks
    Finance

    EVP, CHIEF ADMIN. OFFICER Davis Jane Ann covered exercise/tax liability with 291 shares and was granted 1,230 shares, increasing direct ownership by 8% to 12,739 units (SEC Form 4)

    4 - Carter Bankshares, Inc. (0001829576) (Issuer)

    2/27/26 11:55:44 AM ET
    $CARE
    Major Banks
    Finance

    $ABTX
    $ADVM
    $ALEC
    $AMTI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Stallings Robert W bought $888,000 worth of Depositary Shares for Series B Preferred Stock (40,000 units at $22.20) (SEC Form 4)

    4 - TEXAS CAPITAL BANCSHARES INC/TX (0001077428) (Issuer)

    2/25/26 4:39:54 PM ET
    $TCBI
    Major Banks
    Finance

    Director Stallings Robert W bought $221,280 worth of Depositary Shares for Series B Preferred Stock (10,000 units at $22.13) (SEC Form 4)

    4 - TEXAS CAPITAL BANCSHARES INC/TX (0001077428) (Issuer)

    2/19/26 4:05:16 PM ET
    $TCBI
    Major Banks
    Finance

    Director Zimmer James Edwin bought $9,474 worth of shares (217 units at $43.66) (SEC Form 4)

    4 - FIRST MID BANCSHARES, INC. (0000700565) (Issuer)

    2/18/26 10:46:34 AM ET
    $FMBH
    Major Banks
    Finance

    $ABTX
    $ADVM
    $ALEC
    $AMTI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Blend to Announce Fourth Quarter 2025 Financial Results on March 10, 2026

    Blend Labs, Inc. (NYSE:BLND), a leading digital origination platform, today announced that the Company's fourth quarter 2025 financial results will be released after market close on Tuesday, March 10, 2026. The Company will host a conference call to discuss its results at 1:30 p.m. PT / 4:30 p.m. ET the same day. A link to the live call can be accessed at the Company's Investor Relations website at investor.blend.com, along with the Company's earnings press release, financial information, and slide presentation. Following the call, a replay will be available at the same website. About Blend Blend Labs Inc., (NYSE:BLND) is a leading origination platform for digital banking solutions. F

    2/27/26 4:00:00 PM ET
    $BLND
    Computer Software: Programming Data Processing
    Technology

    KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer

    KEYTRUDA plus paclitaxel with or without bevacizumab is the first PD-1 inhibitor-based regimen to show a statistically significant improvement in OS regardless of PD-L1 status Results from the final analysis of the Phase 3 KEYNOTE-B96 trial to be presented during a Best Oral Session at the European Society of Gynaecological Oncology 2026 Congress Positive EU CHMP opinion granted for KEYTRUDA plus paclitaxel with or without bevacizumab in certain adults with PD-L1 (CPS ≥1) platinum-resistant ovarian carcinoma who have received one or two prior systemic treatment regimens Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced results from the final analy

    2/27/26 10:15:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VTEX's 2025 Annual Report on Form 20-F Available on Our Website

    VTEX (NYSE:VTEX), the backbone for connected commerce, announces that the Company's annual report on Form 20-F for the year ended December 31, 2025 was filed with the U.S. Securities and Exchange Commission - SEC (www.sec.gov/edgar/) on February 26, 2026 and is available on the Company's website (/www.investors.vtex.com/) and also on the Company's page on SEC's database (www.sec.gov/edgar/browse/?CIK=1793663&owner=exclude). Class A common shareholders may receive a hard copy of the Company's complete audited financial statements contained in the Form 20-F free of charge upon request. To access the whole document, please access the following links: https://www.investors.vtex.com/financials

    2/26/26 5:00:00 PM ET
    $VTEX
    Computer Software: Prepackaged Software
    Technology

    $ABTX
    $ADVM
    $ALEC
    $AMTI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Duolingo downgraded by Truist with a new price target

    Truist downgraded Duolingo from Buy to Hold and set a new price target of $100.00

    2/27/26 12:55:49 PM ET
    $DUOL
    Computer Software: Prepackaged Software
    Technology

    Duolingo downgraded by BofA Securities with a new price target

    BofA Securities downgraded Duolingo from Buy to Neutral and set a new price target of $100.00

    2/27/26 10:22:22 AM ET
    $DUOL
    Computer Software: Prepackaged Software
    Technology

    Duolingo downgraded by Scotiabank with a new price target

    Scotiabank downgraded Duolingo from Sector Outperform to Sector Perform and set a new price target of $100.00

    2/27/26 8:28:05 AM ET
    $DUOL
    Computer Software: Prepackaged Software
    Technology

    $ABTX
    $ADVM
    $ALEC
    $AMTI
    Financials

    Live finance-specific insights

    View All

    Blend to Announce Fourth Quarter 2025 Financial Results on March 10, 2026

    Blend Labs, Inc. (NYSE:BLND), a leading digital origination platform, today announced that the Company's fourth quarter 2025 financial results will be released after market close on Tuesday, March 10, 2026. The Company will host a conference call to discuss its results at 1:30 p.m. PT / 4:30 p.m. ET the same day. A link to the live call can be accessed at the Company's Investor Relations website at investor.blend.com, along with the Company's earnings press release, financial information, and slide presentation. Following the call, a replay will be available at the same website. About Blend Blend Labs Inc., (NYSE:BLND) is a leading origination platform for digital banking solutions. F

    2/27/26 4:00:00 PM ET
    $BLND
    Computer Software: Programming Data Processing
    Technology

    Lamar Advertising Company Announces Cash Dividend on Common Stock & Extension of Stock and Debt Repurchase Programs

    BATON ROUGE, La., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Lamar Advertising Company (NASDAQ:LAMR), a leading owner and operator of outdoor advertising and logo sign displays, announces that its board of directors has declared a quarterly cash dividend of $1.60 per share payable on March 31, 2026 to stockholders of record of Lamar's Class A common stock and Class B common stock on March 16, 2026. Subject to the approval of its board of directors, Lamar expects aggregate quarterly distributions to stockholders in 2026, including the dividend payable on March 31, 2026, will total at least $6.40 per common share. In addition, Lamar announces that its board of directors has authorized the extension

    2/26/26 4:15:00 PM ET
    $LAMR
    Real Estate Investment Trusts
    Real Estate

    VTEX Reports Fourth Quarter and Fiscal Year 2025 Financial Results

    GMV & Revenue (Q4): GMV +17.2% (10.0% FXN) and subscription revenue +12.2% (5.4% FXN) Enterprise Focus (FY25): US$250k+ ARR customers reached 158; cohort revenue +13.4% (14.5% FXN) Global Expansion (FY25): Global Markets1 (US/Europe-led) subscription revenue +21.6% (19.2% FXN) Profitability (Q4): Non-GAAP income from operations +31.8% to US$16.2 million (23.8% margin) VTEX (NYSE:VTEX), the backbone for connected commerce, today announced results for the fourth quarter and fiscal year 2025 ended December 31, 2025. VTEX results have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") as well as the rules and regulatio

    2/26/26 4:01:00 PM ET
    $VTEX
    Computer Software: Prepackaged Software
    Technology

    $ABTX
    $ADVM
    $ALEC
    $AMTI
    Leadership Updates

    Live Leadership Updates

    View All

    FS Bancorp, Inc. and Pacific West Bancorp to Merge

    MOUNTLAKE TERRACE, Wash., Feb. 25, 2026 (GLOBE NEWSWIRE) -- FS Bancorp, Inc. ("FS Bancorp") (NASDAQ:FSBW) and Pacific West Bancorp ("Pacific West") (OTCPK: PWBK) announced today the signing of a definitive merger agreement and plan of merger (the "Agreement") whereby Pacific West will merge into FS Bancorp in a stock and cash transaction valued at approximately $34.6 million. As of December 31, 2025, on a pro forma consolidated basis, the combined company would have approximately $3.6 billion in assets, $3.0 billion in loans, $3.0 billion in deposits, and 31 branch locations throughout the Pacific Northwest. Pacific West, headquartered in West Linn, Oregon, is the holding company for Paci

    2/25/26 9:00:00 PM ET
    $FSBW
    Banks
    Finance

    Kohl's Corporation Declares Quarterly Dividend

    The Board of Directors of Kohl's Corporation (NYSE:KSS) ("Kohl's" or the "Company") today declared a regular quarterly dividend of $0.125 per share on the Company's common stock. The dividend is payable April 1, 2026, to shareholders of record at the close of business on March 18, 2026. About Kohl's Kohl's (NYSE:KSS) is a leading omnichannel retailer built on a foundation that combines great brands, incredible value and convenience for our customers. Kohl's is uniquely positioned to deliver against its long-term strategy and its purpose to take care of families' realest moments. Kohl's serves millions of families in its more than 1,100 stores in 49 states, online at Kohls.com, and throu

    2/25/26 4:15:00 PM ET
    $KSS
    Department/Specialty Retail Stores
    Consumer Discretionary

    Merck Evolves Human Health Operating Structure to Support Portfolio Execution

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today highlighted steps to evolve the structure of its Human Health organization to ensure strong commercial execution of launches across diverse therapeutic areas, positioning the company for continued commercial success. As part of this evolution, Merck is organizing its Human Health business into an Oncology Business Unit and a Specialty, Pharma & Infectious Diseases Business Unit. This structure will enable Merck to sustain long-term leadership in oncology, while maintaining a sharp focus in support of a growing number of launches across an increasingly broad and diverse portfolio. In support of the new Human He

    2/23/26 6:45:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABTX
    $ADVM
    $ALEC
    $AMTI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Tenaris S.A.

    SC 13D/A - TENARIS SA (0001190723) (Subject)

    12/9/24 4:53:51 PM ET
    $TS
    Steel/Iron Ore
    Industrials

    SEC Form SC 13G filed by Alector Inc.

    SC 13G - Alector, Inc. (0001653087) (Subject)

    12/6/24 5:30:28 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by PNC Financial Services Group Inc.

    SC 13G/A - PNC FINANCIAL SERVICES GROUP, INC. (0000713676) (Filed by)

    11/14/24 8:22:26 PM ET
    $PNC
    Major Banks
    Finance

    $ABTX
    $ADVM
    $ALEC
    $AMTI
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Breaking: Stock Acquired at Athira Pharma Inc. on Jun 25

    Recently, on June 25, 2024, Director Romano Kelly A bought $100,051 worth of shares in Athira Pharma Inc. This transaction involved acquiring 42,400 units at $2.36 per share, resulting in a significant increase in direct ownership by 111% to 80,715 units. The purchase was disclosed in the SEC Form 4 filing. Insider buying is often considered a bullish signal as insiders may have insights into the company's future performance. It's essential to analyze this insider purchase in conjunction with previous insider transactions to identify any patterns or trends. Taking into account the information from the SEC filings, several other insiders at Athira Pharma Inc. have also been active in the sto

    6/26/24 3:07:15 PM ET
    $ATHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care